Antares Pharma Receives a New Rating from H.C. Wainwright

By Carrie Williams

Antares Pharma (NASDAQ: ATRS) received a Buy rating and a $5 price target from H.C. Wainwright analyst Oren Livnat on September 8. The company’s shares closed on Friday at $3.04, close to its 52-week high of $3.37.

According to TipRanks.com, Livnat is ranked #3870 out of 4633 analysts.

Currently, the analyst consensus on Antares Pharma is Strong Buy and the average price target is $5, representing a 64.5% upside.

In a report issued on September 5, Piper Jaffray also reiterated a Buy rating on the stock with a $4 price target.

The company has a one year high of $3.37 and a one year low of $1.27. Currently, Antares Pharma has an average volume of 1.38M.

Based on the recent corporate insider activity of 17 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ATRS in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Antares Pharma, Inc. is a pharmaceutical company. The company focuses on the development and commercialization of self-administered parenteral pharmaceutical products and technologies. Its activities include the development of injection devices and injection based pharmaceutical products as well as transdermal gel products.